Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants

Trial Profile

A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Sugammadex (Primary) ; Atropine; Glycopyrrolate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Aug 2018 Planned End Date changed from 23 Sep 2020 to 24 Sep 2020.
    • 05 Mar 2018 Planned primary completion date changed from 9 Sep 2020 to 7 Sep 2020.
    • 19 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top